Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Add-on docetaxel confers survival advantage in ICI-naïve NSCLC, with caveat

Add-on docetaxel confers survival advantage in ICI-naïve NSCLC, with caveat

20 Oct 2022

In the treatment of patients with ICI-naïve nonsmall cell lung cancer (NSCLC), adding the cytotoxic chemotherapy docetaxel to the immune-checkpoint inhibitor (ICI) nivolumab leads to a significantly longer survival, although at the expense of slightly elevated toxicity, according to the results of a phase II/III trial.

20 Oct 2022
Timely treatment of melanoma helps improve patient survival

Timely treatment of melanoma helps improve patient survival

16 Oct 2022

Delays in the treatment of melanoma may worsen overall (OM) and melanoma-specific mortality (MSM), suggest the results of a recent study.

16 Oct 2022